We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Repeatability and Reproducibility of Multiparametric MRI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03743272
Recruitment Status : Unknown
Verified May 2021 by Perspectum.
Recruitment status was:  Recruiting
First Posted : November 16, 2018
Last Update Posted : August 3, 2021
Information provided by (Responsible Party):

Brief Summary:
This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS, Perspectum Diagnostics, Oxford, UK) protocol across different field strengths, scanner manufacturers and models.

Condition or disease Intervention/treatment
Liver Diseases Primary Biliary Cirrhosis Non-Alcoholic Fatty Liver Disease Non-Alcoholic Steatohepatitis Cirrhosis Hemochromatosis Viral Hepatitis Autoimmune Hepatitis Primary Sclerosing Cholangitis Device: LiverMultiScan

Detailed Description:

As the burden of liver disease reaches epidemic levels, there is a high unmet medical need to develop robust, accurate and reproducible non-invasive methods to quantify liver tissue characteristics for use in clinical development and ultimately in clinical practice. Repeatability and reproducibility validation studies are important in evaluating metrics, such that any changes can be confidently attributed to disease progression or regression, rather than inter-examination variability in the instrument.

Magnetic resonance (MR) techniques offer an attractive non-invasive option for liver assessment. Multiparametric MRI is a safe and non-invasive method for quantification of liver tissue characteristics. Images for quantification of hepatic fat from proton density fat fraction (PDFF) maps, T2*, and iron-corrected T1 (cT1) can be rapidly obtained during abdominal breath-hold acquisitions without the need for contrast agents or additional external hardware. Iron correction of T1 is necessary to address the confounding effects of excess iron, which is common in chronic liver disease. LiverMultiScan™ (LMS, Perspectum Diagnostics, Oxford, UK) is a software application that can be used with supported MR-systems to correct T1 for the effects of excess iron, and thus, to calculate cT1 from T1 and T2* maps, and standardise to a 3T field strength.

This method has been shown to have high diagnostic accuracy for the assessment of liver fibrosis compared to histology, predict clinical outcomes in patients with mixed liver disease aetiology, stratify patients with non-alcoholic steatohepatitis (NASH) and cirrhosis, reliably exclude clinically significant liver disease and is cost-effective in diagnosing NAFLD.

In addition to demonstrating accuracy, imaging biomarker validation requires precision and repeatability (US Department of Health and Human Services, 2015). From a clinical perspective, it is essential to ensure that there is good inter-examination repeatability, so that any changes seen can be correctly attributed to disease progression or regression, rather than inter-examination variability. This is tested by examining the closeness of repeated measurements made in different MR examinations (with both subject and coil repositioning) over a time frame in which physiologic conditions are assumed constant.

This study aims to systematically test the repeatability and reproducibility of each multiparametric MRI measurement, cT1, T2* and PDFF, corresponding to hepatic fibro-inflammation, iron and fat respectively, across scanner field strength, manufacturer and model in human participants and phantoms.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 61 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Repeatability and Reproducibility of Multiparametric MRI (LiverMultiScan)
Actual Study Start Date : June 3, 2017
Estimated Primary Completion Date : June 17, 2022
Estimated Study Completion Date : November 1, 2022

Group/Cohort Intervention/treatment
Liver condition
Participants who have a history of of liver disease
Device: LiverMultiScan
Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
Other Name: Multiparametric Magnetic Resonance Imaging (mpMRI)

Healthy volunteers
Participants who have do not have a diagnosed liver condition and are in general good health
Device: LiverMultiScan
Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
Other Name: Multiparametric Magnetic Resonance Imaging (mpMRI)

Primary Outcome Measures :
  1. Repeatability [ Time Frame: 2 years ]
    Comparison of multi-parametric MRI measures (MRI-PDFF, T2* and iron-corrected T1 (cT1)) from repeated acquisitions of the same participant on the same scanner.

  2. Reproducibility [ Time Frame: 2 years ]
    Comparison of multi-parametric MRI measures (MRI-PDFF, T2* and iron-corrected T1 (cT1)) from repeated acquisitions of the same participant on different scanners (1.5T and 3.0T).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Participants are those with mixed liver disease aetiology and those without any history of liver disease in order to represent a wide range of values of hepatic fat, iron, and fibro-inflammatory status.

Inclusion Criteria:

  • Any person over 18 years of age.
  • Participant is willing and able to give informed consent.

Exclusion Criteria:

  • The participant may not enter the study if they have any contraindication to magnetic resonance imaging (inc pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia).
  • Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study or affect the participant's ability to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03743272

Layout table for location contacts
Contact: Soubera Rymell, BSc +441865655343 soubera.rymell@perspectum.com
Contact: Velicia Bachtiar, DPhil +441865655343 velicia.bachtiar@perspectum-diagnostics.com

Layout table for location information
Leiden University Medical Centre Active, not recruiting
Leiden, Netherlands
United Kingdom
Addenbrookes Hospital Completed
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR) Recruiting
Oxford, Oxfordshire, United Kingdom, OX3 9DU
Contact: Kathryn Lacey    +441865220245    kathryn.lacey@cardiov.ox.ac.uk   
Southampton General Hospital Active, not recruiting
Southampton, United Kingdom
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Rajarshi Banerjee, BM BCh MS DPhil Perspectum Diagnostics
Layout table for additonal information
Responsible Party: Perspectum
ClinicalTrials.gov Identifier: NCT03743272    
Other Study ID Numbers: LMSRR
First Posted: November 16, 2018    Key Record Dates
Last Update Posted: August 3, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Perspectum:
Multiparametric MRI
Liver MRI
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Liver Cirrhosis
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Cholangitis, Sclerosing
Liver Cirrhosis, Biliary
Hepatitis, Autoimmune
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Pathologic Processes
Bile Duct Diseases
Biliary Tract Diseases
Cholestasis, Intrahepatic
Hepatitis, Chronic
Autoimmune Diseases
Immune System Diseases
Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors